Regeneron Pharmaceuticals, Inc. $REGN Shares Newly Bought by Cantor Fitzgerald Investment Advisors L.P.

Key Points

• Cantor Fitzgerald Investment Advisors purchased 24,900 Regeneron shares worth approximately $18.9 million in the third quarter. Institutional investors and hedge funds collectively own 83.31% of the company.
• Analysts maintain a favorable outlook, with a consensus rating of “Moderate Buy” and an average price target of $846.28. Several firms recently raised their targets, including HSBC to $920.
• Regeneron reported quarterly EPS of $14.29, beating estimates by $4.13, while revenue rose 16.7% year over year to $4.29 billion. The company also pays a quarterly dividend of $0.94 per share, yielding approximately 0.5%.

Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 24,900 shares of the biopharmaceutical company's stock, valued at approximately $18,881,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Orbimed Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $11,358,000. BlackRock Inc. acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $5,682,636,000. Contravisory Investment Management Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $6,327,000. Oxbow Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $3,342,000. Finally, Deutsche Bank AG acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $323,249,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company increased their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research note on Friday, July 31st. Citigroup lifted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a report on Monday, August 3rd. HSBC upped their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Robert W. Baird upped their price target on shares of Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a "neutral" rating in a research note on Friday, July 31st. Finally, Royal Bank Of Canada increased their price target on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a "sector perform" rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $846.28.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the transaction, the executive vice president directly owned 13,134 shares of the company's stock, valued at approximately $11,163,900. The trade was a 8.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Murphy sold 4,147 shares of the firm's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the sale, the insider owned 47,833 shares of the company's stock, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock worth $6,506,845 in the last three months. Corporate insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Trading Down 0.2%

Shares of Regeneron Pharmaceuticals stock opened at $805.67 on Thursday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12-month low of $572.75 and a 12-month high of $859.34. The company has a market capitalization of $82.95 billion, a price-to-earnings ratio of 19.91, a PEG ratio of 1.37 and a beta of 0.16. The firm's 50-day moving average price is $791.56 and its two-hundred day moving average price is $722.18.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The company had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same quarter in the previous year, the firm earned $12.81 EPS. Regeneron Pharmaceuticals's revenue was up 16.7% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 48.87 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.